astrocytoma/diare

Tautan disimpan ke clipboard

Pilih jenis pengurutan

Halaman 1 dari 26 hasil

Pilot study of combination 5-fluorouracil, cisdiamminedichloroplatinum II, and radiation therapy for grade III and IV astrocytomas.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Nineteen patients with biopsy-proven high-grade astrocytomas received as initial treatment whole-brain radiation and combination chemotherapy with 5-fluorouracil (5-FU), 1,000 mg/m2/24 h as a continuous infusion for 96 h, and bolus cisdiamminedichloroplatinum II (CDDP), 100 mg/m2. Chemotherapy

Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Twenty patients with astrocytomas recurrent after surgery +/- radiation were treated on a phase II protocol of the new anthracycline derivative menogaril 115 mg/m2 administered intravenously once per week. Sixteen patients were evaluable for treatment efficacy. No patient achieved a major

Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS). METHODS Forty patients (27 men and 13 women) ages 17 to 58 years (median age, 38

Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT). However, the optimal schedule of administration is unknown. METHODS In the present study, a total of 45 HGAT patients, 38 with glioblastoma multiforme (GBM) and

Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

We evaluated the safety and survival benefits of orally administered erlotinib monotherapy for patients with relapsed/refractory glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA). A dose escalation schedule was administered with a starting dose of 150 mg/day for the first cycle (28 days),

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

OBJECTIVE Amplification of the epidermal growth factor receptor (EGFR) gene represents one of the most frequent gene alterations in glioblastoma (GBM). In the current study, we evaluated gefitinib, a potent EGFR inhibitor, in the treatment of adults with newly diagnosed GBM. METHODS Ninety-eight

Recurrent cerebellar gliomas: salvage therapy with oral etoposide.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

The purpose of this investigation was to assess the toxicity and activity of chronic oral etoposide in the management of children with recurrent juvenile pilocytic cerebellar astrocytomas. Twelve children with recurrent juvenile pilocytic cerebellar astrocytomas, refractory to surgical resection,

Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND A long-term regimen of oral etoposide, a type of chemotherapy, is used in oncology and is effective in treating germ-cell tumors, lymphomas, Kaposi sarcoma, and primary brain tumors. OBJECTIVE To examine the toxic effects and efficacy of long-term salvage chemotherapy using oral

Etoposide-containing regimens with autologous bone marrow transplantation in children with malignant brain tumors.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Despite improvements in neurosurgical and neuroradiotherapeutic techniques, children with malignant brain tumors have a dismal prognosis. In an attempt to improve the efficacy of cytotoxic therapy, dose intensification of effective chemotherapeutic agents followed by autologous bone marrow

Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Patients with recurrence of high-grade glioma (HGG) after bevacizumab (BEV) have an extremely poor prognosis. Etirinotecan pegol (EP) is the first long-acting topoisomerase-I inhibitor designed to concentrate in and provide continuous tumor exposure throughout the entire chemotherapy cycle. Here we

Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Pediatric gliosarcoma (GS) is a rare variant of glioblastoma multiforme. The authors describe the case of an unusual pontine location of GS in a 9-year-old boy who was initially diagnosed with low-grade astrocytoma (LGA) that was successfully controlled for 4 years. Subsequently, his brain tumor

[Diagnostic difficulties in encephalitis and glioma].

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Glial neoplasms can infiltrate the central nervous system extensively with relative preservation of the underlying neuronal architecture. The differential diagnosis between cerebral glioma and infective lesions can be very difficult to distinguish by MRI only. METHODS We report a 7 year

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG). We previously established the maximum tolerated dose of CPT-11 when administered for 4 consecutive weeks in combination

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratified patients into astrocytoma and

Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

To evaluate the anticancer agent flavone acetic acid (FAA), we conducted a Phase I trial involving 17 pediatric patients with various malignant solid tumors. Dosages investigated included 5,120 and 6,144 mg/m2 given as 3-hour intravenous infusions; and 10,000, 12,500, 15,000, and 17,500 mg/m2

Sebelumnya
1
2
Lanjut

Bergabunglah dengan
halaman facebook kami

Herbal & Natural Medicine

Database tanaman obat terlengkap yang didukung oleh sains

Bekerja dalam 55 bahasa
Pengobatan herbal didukung oleh sains
Pengenalan herbal melalui gambar
Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
Baca publikasi ilmiah yang terkait dengan pencarian Anda
Cari tanaman obat berdasarkan efeknya
Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten

Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan